The United States Food and Drug Administration (USFDA) has given Prior Approval Supplement (PAS) approval to Alembic Pharma’s supplemental Abbreviated New Drug Application (sANDA) Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.

The ANDA, submitted as a "Prior Approval Supplement," specifies an alternate drug product manufacturing site for previously approved ANDAs from Panelav Facility (F-I) - Alembic Pharma, Formulation Division IV, Jarod, Gujarat.

The Jarod Facility was inspected in December 2022 and this is the first product approval from that facility, according to a statement from the business.

The approved sANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Lyrica Capsules, of Upjohn.

Pregabalin Capsules are indicated for neuropathic pain, postherpetic neuralgia, and other indications, the statement concluded.

USFDA gives approval for Brivaracetam Tablets

USFDA approves Gene Therapy for Bladder Cance

USFDA approves this lung cancer drug

USFDA gives nod for Silodosin, Pregabalin Capsules

USFDA gives final approval for Desonide cream

USFDA gives nod for Diclofenac Sodium topical solution

Kerala to cancel licences of Medical Stores selling antibiotics without prescription

USFDA gives approval for Brivaracetam Tablets

NPPA fixes Retail Price of 12 scheduled formulations: December 2022

NPPA revises Retail Price of 107 scheduled formulations: December 2022

NABL asks Testing Laboratories to get product based accreditation

Goa FDA allows manufacture and marketing of Ulipristal Acetate Tablets 5mg

Drug Regulators sought Pharmacovigilance (PV) for Gabapentin and Pregabalin

DCOIWA: Workshop on Medical Device Regulation and Legal Documentation organized

Bulk transfer of Blood and Blood Components: Procedure and Conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/22/usfda-gives-approval-for-pregabalin-capsules/